Product Description
Mechanisms of Action: D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Bulimia Nervosa|Anorexia|Malnutrition|Substance Abuse Unspecified
Phase 2: Healthy Volunteers|Parkinson's Disease
Phase 1: Opioid-Related Disorders|Depressive Disorder|Obesity|Overweight|Traumatic Brain Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
17-AA-0114 | P1 |
Recruiting |
Opioid-Related Disorders |
2025-12-31 |
|
NCT03999190 | N/A |
Withdrawn |
Schizophrenia |
2025-07-01 |
|
14-N-0083 | P1 |
Completed |
Traumatic Brain Injury |
2024-02-13 |
|
18-DK-0132 | P1 |
Completed |
Overweight|Obesity |
2022-03-31 |